The poor generalizability of clinical research data due to the enrollment of highly educated,
non‐Latinx White participants hampers the development of therapies for Alzheimer's …

Blacks/African Americans have been reported to be∼ 2–4 times more likely to develop
clinical Alzheimer's disease (AD) compared to Whites. Unfortunately, study design …

Personalized medicine aims to tailor diagnosis and treatment based on an individual's
personal genetic make-up and other predictive biomarkers—rather than a one-size fits all …

Importance Underrepresentation of many racial/ethnic groups in Alzheimer disease (AD)
clinical trials limits generalizability of results and hinders opportunities to examine potential …

Clinical Alzheimer's disease (AD) trials currently face a critical shortfall of thousands of
eligible participants, which inflates the duration and cost of the clinical study as well as …

To generalize findings on the mechanisms and prognosis in Alzheimer's disease and
related dementias (ADRD), it is critical for ADRD research to be representative of the …

Introduction Updated estimates of the US Alzheimer's disease (AD) population, including
under‐represented populations, are needed to improve clinical trial diversity. Methods A …

Abstract Introduction Black Americans are disproportionately burdened by Alzheimer's
disease (AD) relative to other racial groups in the United States and continue to be …

Objective The authors investigated potential effects of increased African American
participation in Alzheimer disease (AD) and mild cognitive impairment (MCI) clinical trials by …

In the search for treatments to delay or halt the progression of Alzheimer disease (AD),
researchers see promise in clinical trials that enroll people without cognitive decline who …